Adopting a strategy that lives up to the tagline ‘Reset, Resurgent’ that its investor presentations begins with, Strides Pharma Science Ltd. plans to repurpose some existing medicines for COVID-19 while counting on new products to fill the gap in revenues left by ranitidine after its withdrawal from the US market this April post a request by the US Food and Drug Administration (FDA).
During the fourth quarter to March, Strides reported marginally higher consolidated revenues of INR6.36bn ($83.8m) versus INR6.33bn for the same...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
